Acurx Pharmaceuticals

Management has focused spend to prepare for Phase 3 and initiated a small open‑label rCDI pilot to refine design and positioning. IP has been expanded, and regulatory interactions have been leveraged to clarify development. However, reliance on ATMs, warrant inducements, and equity lines reflects constrained financing optionality.

No evidence yet of favorable non‑dilutive funding or partnering that would materially improve shareholder economics.